Source: International Congress 2018 – Variant forms of asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. O'Byrne (Hamilton, Canada), J. Fitzgerald (Vancouver, Canada), E. Bateman (Cape Town, South Africa), P. Barnes (London, United Kingdom), N. Zhong (Guangzhou, China), C. Keen (Gothenburg, Sweden), M. Wang (Cambridge, United Kingdom), R. Lamarca (Barcelona, Spain), M. Puu (Gothenburg, Sweden), H. Reddel (Sydney, Australia). Late Breaking Abstract - Risk of a severe exacerbation following higher reliever use: post-hoc analysis of SYGMA 1 in mild asthma. 1680

Member's Comments

No comment yet.

Related content which might interest you: Late Breaking Abstract - Extrafine triple therapy reduces exacerbations in GOLD B COPD patients: post-hoc analysis of TRILOGY and TRINITY Source: International Congress 2017 – Update and new perspectives in Airway Diseases Year: 2017 Late Breaking Abstract - Reduction of COPD exacerbations with extrafine single inhaler triple therapy: post-hoc analysis by exacerbation treatment of the TRIBUTE study Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Identification of factors associated with exacerbation risk in severe COPD: Multivariate analysis of the WISDOM study Source: International Congress 2016 – Pharmacological management of COPD Year: 2016 Number needed to treat (NNT) to have an additional patient free from a severe or moderate/severe exacerbation: post-hoc analysis of SYGMA 1 in mild asthma Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Clinical characteristics and outcomes of elderly patients with COPD: TIOSPIR® post-hoc analysis Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Late Breaking Abstract - Effect of inhaled corticosteroids on exacerbation of asthma–COPD overlap according to different diagnostic criteria Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more Year: 2019 Late Breaking Abstract - Corticosteroid optimisation in severe asthma using composite biomarkers to adjust dose versus a symptom/risk-based algorithm Source: Virtual Congress 2020 – ALERT: Asthma in adults and children Year: 2020 Late Breaking Abstract - COPD exacerbation benefits relative to pneumonia risk with budesonide/glycopyrronium/formoterol metered dose inhaler: analyses from ETHOS Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020 Late Breaking Abstract - Can a self-management plan, which includes a four-fold increase in inhaled corticosteroid dose, reduce severe asthma exacerbations: a randomised, pragmatic trial. Source: International Congress 2017 – Late-breaking findings in asthma and COPD Year: 2017 Severe asthma: classification and treatment Source: Virtual Congress 2021 – Clinical year in review Year: 2021 Effect of high extrafine strength (HS) ICS-containing triple therapy on exacerbations in patients with severe asthma and persistent airflow limitation: Post-hoc analysis of the TRIGGER study Source: International Congress 2019 – Novel findings from asthma clinical trials Year: 2019 Respiratory effectiveness group study: Predictors of frequent severe asthma exacerbations Source: International Congress 2015 – Management of asthma and COPD in primary care Year: 2015 Baseline symptom scores and future risk of severe exacerbation: The SPARK study Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015 Late Breaking Abstract - Indacaterol/glycopyrronium versus salmeterol/fluticasone in chronic obstructive pulmonary disease: a meta-analysis on the protection against the risk of exacerbation Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Session 1: Characterisation and features of severe exacerbations of COPD - General discussion Source: Research Seminar 2021 – Unravelling severe exacerbations of COPD – CICERO an ERS CRC Year: 2021 Characteristics and medication use of the patients with acute exacerbations of asthma-COPD overlap syndrome Source: International Congress 2015 – Is asthma always an easy disease to diagnose and manage? Year: 2015 Preventing asthma exacerbations with budesonide/formoterol maintenance + relief: a pooled analysis Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of pulmonary diseases II Year: 2008 Dupilumab reduces severe exacerbations in periostin-high and periostin-low asthma patients Source: International Congress 2016 – Asthma: from basic mechanisms to novel therapeutic perspectives Year: 2016 Late Breaking Abstract - Danirixin (GSK1325756) improves respiratory symptoms and health status in mild to moderate COPD – results of a 1 year first time in patient study Source: International Congress 2017 – Primary care management of respiratory symptoms, allergies, inhalers and adherence Year: 2017 Predictors of severe asthma exacerbations, poor asthma control and beta-agonist overuse in adult asthma Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013